Delivery of pharmaceutical products for treatment of oncological and hematological diseases and blood coagulation factors for the needs of UMBAL Dr. Georgi Stranski EAD - Pleven
Titre original de l'avis
Bulgaria – Pharmaceutical products – „Доставка на лекарствени продукти за лечение на онкологични и хематологични заболявания и фактори за кръвосъсирване за нуждите на УМБАЛ „Д-р Георги Странски” ЕАД - Плевен”
Score d'opportunité
Pourquoi ce score ?
Opportunité
70 / 100
Complexité
60 / 100
Facteurs de risque
Structured data indicates EU funding, but XML notice states 'no-eu-funds'. This could affect contract terms or budget.
Requires specific wholesale and possibly manufacturer authorizations for each product, which may narrow the field of el...
Restricted procedure — pre-qualification required
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Strong opportunityFaits clés
- BGN 324.7M estimated value
- Dynamic Purchasing System (DPS)
- Supplies contract
- 1 lot
- Duration 36 MONTH
- Delivery of pharmaceutical products for oncology and hematology
- Delivery of blood coagulation factors
Afficher le résumé complet
This is a restricted procedure for a Dynamic Purchasing System (DPS) for the supply of pharmaceutical products for oncological and hematological diseases and blood coagulation factors to the University Hospital Dr. Georgi Stranski in Pleven, Bulgaria. The estimated value is 324,733,078.61 BGN, with a duration of 36 months. The deadline for submission is 2028-05-02. The award is based on lowest price.
Risques
Structured data indicates EU funding, but XML notice states 'no-eu-funds'. This could affect contract terms or budget.
Requires specific wholesale and possibly manufacturer authorizations for each product, which may narrow the field of el...
Restricted procedure — pre-qualification required
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Must be a registered trader permitted to wholesale medicinal products
- Must hold a wholesale authorization for medicinal products from the Bulgarian Drug Agency (IAL) or equivalent from another EU member state
- If manufacturer, must hold production authorization or authorization from the product manufacturer
Les exigences peuvent être incomplètes.
Critères d'attribution
Lot 1
Acheteur
Localisation
гр. Плевен, BGR
Profil acheteur
Identifiant
114532352
Activité
Health
Lots (1)
LOT-0001
Delivery of pharmaceutical products for treatment of oncological and hematological diseases and blood coagulation factors for the needs of UMBAL Dr. Georgi Stranski EAD - Pleven
Supply of oncological and hematological medicines and blood clotting factors as per technical specifications. The lot is a DPS with continuous competition.
BGN 324.7M
Valeur estimée
Localisation
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
На първо място се класира участникът, предложил най-ниска цена. Останалите оферти заемат места в класирането по низходящ ред
Note sur la valeur
Afficher les données TED originales
Titre original du lot
„Доставка на лекарствени продукти за лечение на онкологични и хематологични заболявания и фактори за кръвосъсирване за нуждите на УМБАЛ „Д-р Георги Странски” ЕАД - Плевен”
Description TED originale
Процедура по реда на Закона за обществените поръчки за лекарствени продукти за лечение на онкологични и хематологични и фактори за кръвосъсирване за нуждите на „УМБАЛ Д-р Георги Странски” ЕАД – Плевен,, по смисъла на Закона за лекарствените продукти в хуманната медицина , съгласно техническата спецификация и условията на настоящата документация.
Détails de la procédure
- Date de publication
- 02 Apr 2025
- Langues
- Bulgarian
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 216830-2025
Documents (1)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
70 / 100
Complexité
60 / 100
Facteurs de risque
Structured data indicates EU funding, but XML notice states 'no-eu-funds'. This could affect contract terms or budget.
Requires specific wholesale and possibly manufacturer authorizations for each product, which may narrow the field of el...
Restricted procedure — pre-qualification required
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications